Ehlers-Danlos Syndrome (Vascular Type)

Overview


Plain-Language Overview

Ehlers-Danlos Syndrome (Vascular Type) is a rare genetic disorder that affects the body's connective tissues, which provide strength and support to the skin, blood vessels, and organs. This condition primarily impacts the vascular system, making blood vessels fragile and prone to rupture. People with this syndrome often have very thin, translucent skin and may experience easy bruising. The disorder can lead to serious complications such as arterial rupture, which can be life-threatening. It also affects the heart valves and internal organs, increasing the risk of spontaneous tears. Because of these risks, individuals with this condition require careful monitoring of their cardiovascular health.

Clinical Definition

Ehlers-Danlos Syndrome (Vascular Type) is a hereditary connective tissue disorder caused by mutations in the COL3A1 gene, which encodes type III collagen, a critical component of blood vessel walls and hollow organs. The core pathology involves defective type III collagen synthesis, leading to fragile and easily ruptured arteries, intestines, and uterus. This subtype is characterized by thin, translucent skin, acrogeria (premature aging of the extremities), and a high risk of spontaneous arterial or organ rupture. It is inherited in an autosomal dominant pattern and is clinically significant due to its association with sudden, life-threatening vascular events. Diagnosis is important for risk stratification and management to prevent fatal complications.

Inciting Event

  • Spontaneous arterial rupture or dissection often triggers clinical presentation.

  • Minor trauma or surgical procedures can precipitate vascular or organ rupture.

  • Pregnancy and labor can provoke uterine or arterial rupture in affected women.

  • Sudden onset of severe pain or hemorrhage may be the first clinical sign.

  • Physical exertion or hypertension can exacerbate risk of vascular events.

Latency Period

  • Symptoms often develop in the second to fourth decade of life after latent collagen defects accumulate.

  • Vascular complications may occur years after initial skin or joint symptoms are noted.

  • Diagnosis is frequently delayed until the first major vascular or organ rupture event.

  • Some patients remain asymptomatic until a catastrophic vascular event occurs.

  • Latency varies widely depending on mutation severity and environmental factors.

Diagnostic Delay

  • Diagnosis is often missed due to overlap with other connective tissue disorders like Marfan syndrome.

  • Lack of awareness of vascular Ehlers-Danlos syndrome leads to misattribution of symptoms to trauma.

  • Mild or nonspecific early signs such as easy bruising and thin skin are overlooked.

  • Genetic testing is underutilized, delaying confirmation of pathogenic COL3A1 mutations.

  • Presentation with sudden vascular events without prior warning complicates early diagnosis.

Clinical Presentation


Signs & Symptoms

  • Spontaneous arterial rupture presenting with sudden pain or hemorrhage is a hallmark symptom.

  • Easy bruising and thin skin prone to tearing and poor wound healing.

  • Characteristic facial features including large eyes, thin nose, and thin lips.

  • Acrogeria or premature aging appearance of the hands and feet.

  • Gastrointestinal perforations and organ rupture may occur due to tissue fragility.

History of Present Illness

  • Patients report recurrent spontaneous bruising and thin, translucent skin with visible veins.

  • History of arterial dissection, aneurysm, or rupture presenting with acute pain and hemorrhage.

  • Episodes of gastrointestinal or uterine rupture causing acute abdomen or obstetric emergencies.

  • Chronic complaints of joint hypermobility and easy tissue injury may be present.

  • Family history often reveals relatives with early sudden death from vascular causes.

Past Medical History

  • Previous episodes of spontaneous arterial rupture or dissection are common.

  • History of easy bruising, poor wound healing, and thin skin since childhood.

  • Prior surgeries complicated by excessive bleeding or poor tissue integrity.

  • Pregnancy-related complications such as uterine rupture or postpartum hemorrhage in women.

  • No history of trauma sufficient to explain severity of vascular or organ rupture.

Family History

  • Autosomal dominant inheritance with multiple affected family members across generations.

  • Relatives with history of spontaneous arterial rupture, aneurysms, or sudden death.

  • Family members diagnosed with vascular Ehlers-Danlos syndrome or related connective tissue disorders.

  • Reports of easy bruising and thin skin in first-degree relatives.

  • Some families have documented COL3A1 mutations confirming genetic diagnosis.

Physical Exam Findings

  • Thin, translucent skin with visible underlying veins, especially on the chest and extremities.

  • Easy bruising with minimal trauma due to fragile blood vessels.

  • Characteristic facial features including a thin nose, thin lips, and prominent eyes.

  • Arterial fragility may be suggested by palpable pulsatile masses or bruits.

  • Joint hypermobility is usually mild or absent compared to other EDS types.

Diagnostic Workup


Diagnostic Criteria

Diagnosis is established based on the presence of characteristic clinical features such as thin, translucent skin, arterial rupture at a young age, and family history consistent with autosomal dominant inheritance. Confirmatory diagnosis requires identification of a pathogenic variant in the COL3A1 gene through molecular genetic testing. Histological examination of affected tissue may show abnormalities in type III collagen. Imaging studies like CT angiography can detect arterial aneurysms or dissections, supporting the diagnosis.

Pathophysiology


Key Mechanisms

  • Mutations in the COL3A1 gene cause defective synthesis of type III collagen, leading to fragile blood vessels and hollow organs.

  • Impaired collagen fibril formation results in reduced tensile strength of vascular and connective tissues.

  • Structural weakness in the arterial walls predisposes to spontaneous rupture and aneurysm formation.

  • Defective extracellular matrix integrity causes skin fragility and easy bruising.

  • Abnormal collagen affects wound healing, increasing risk of complications after surgery or trauma.

InvolvementDetails
Organs

Arteries are critically involved as their walls are fragile and prone to aneurysm formation and rupture, causing life-threatening hemorrhage.

Skin shows thin, translucent appearance with visible veins due to defective connective tissue.

Intestines may be affected by spontaneous rupture due to fragile connective tissue.

Tissues

Vascular connective tissue is weakened, especially in arteries, predisposing to aneurysms and spontaneous rupture.

Cells

Fibroblasts produce defective type III collagen leading to weakened vascular and connective tissue integrity.

Chemical Mediators

Type III collagen is deficient or structurally abnormal due to mutations in the COL3A1 gene, causing vascular fragility.

Treatments


Pharmacological Treatments

  • Beta-blockers (e.g., celiprolol)

    • Mechanism:
      • Reduce arterial wall stress by decreasing heart rate and blood pressure, lowering risk of vascular rupture.

    • Side effects:
      • Bradycardia

      • Fatigue

      • Hypotension

    • Clinical role:
      • First-line

Non-pharmacological Treatments

  • Avoidance of high-impact sports and activities that increase risk of vascular injury or trauma.

  • Regular cardiovascular imaging surveillance to monitor for arterial aneurysms and dissections.

  • Genetic counseling for affected individuals and family members to discuss inheritance and risks.

  • Prompt surgical intervention for life-threatening vascular complications such as arterial rupture.

Prevention


Pharmacological Prevention

  • Beta-blockers such as celiprolol reduce arterial wall stress and risk of rupture.

  • Avoidance of anticoagulants and antiplatelet agents unless absolutely necessary due to bleeding risk.

  • Pain management with non-NSAID analgesics to minimize bleeding risk.

  • Prophylactic antibiotics during invasive procedures to prevent infection in fragile tissues.

Non-pharmacological Prevention

  • Regular vascular imaging surveillance to monitor for aneurysms and dissections.

  • Avoidance of high-impact sports and heavy lifting to reduce vascular stress.

  • Genetic counseling and family screening for early diagnosis and management.

  • Meticulous wound care and avoidance of unnecessary surgeries to prevent complications.

  • Pregnancy management in specialized centers due to high risk of uterine rupture.

Outcome & Complications


Complications

  • Fatal arterial rupture is the most serious complication and leading cause of death.

  • Spontaneous organ rupture including bowel and uterus during pregnancy.

  • Severe hemorrhage from minor trauma or spontaneously.

  • Chronic pain and disability from repeated vascular and soft tissue injuries.

Short-term Sequelae Long-term Sequelae
  • Acute arterial dissection or rupture causing life-threatening hemorrhage.

  • Spontaneous pneumothorax presenting with sudden chest pain and dyspnea.

  • Wound dehiscence and poor healing after minor injuries or surgeries.

  • Acute gastrointestinal perforation leading to peritonitis.

  • Progressive arterial aneurysms and dissections increasing risk of sudden death.

  • Chronic pain and disability from repeated vascular and soft tissue injuries.

  • Premature aging of skin and soft tissues with persistent fragility.

  • Recurrent organ rupture and complications from multiple surgeries.

Differential Diagnoses


Ehlers-Danlos Syndrome (Vascular Type) versus Marfan Syndrome

Ehlers-Danlos Syndrome (Vascular Type)

Marfan Syndrome

Autosomal dominant mutation in COL3A1 gene

Autosomal dominant mutation in FBN1 gene

Thin translucent skin, easy bruising, arterial rupture, characteristic facial features

Tall stature, arachnodactyly, lens dislocation, aortic root dilation

Spontaneous rupture of medium-sized arteries and hollow organs

Aortic root aneurysm and dissection

Ehlers-Danlos Syndrome (Vascular Type) versus Loeys-Dietz Syndrome

Ehlers-Danlos Syndrome (Vascular Type)

Loeys-Dietz Syndrome

Mutations in COL3A1 gene

Mutations in TGFBR1 or TGFBR2 genes

Characteristic thin nose, thin lips, and prominent eyes without bifid uvula

Hypertelorism, bifid uvula or cleft palate

Predominantly medium-sized artery rupture with less arterial tortuosity

Diffuse arterial tortuosity with aneurysms throughout the arterial tree

Ehlers-Danlos Syndrome (Vascular Type) versus Classic Ehlers-Danlos Syndrome (Types I and II)

Ehlers-Danlos Syndrome (Vascular Type)

Classic Ehlers-Danlos Syndrome (Types I and II)

Thin, translucent skin without significant atrophic scarring

Marked skin hyperextensibility and atrophic scarring

Mild to moderate joint hypermobility, less frequent dislocations

Severe joint hypermobility with frequent dislocations

High risk of arterial and organ rupture

Rare vascular rupture

Ehlers-Danlos Syndrome (Vascular Type) versus Pseudoxanthoma Elasticum

Ehlers-Danlos Syndrome (Vascular Type)

Pseudoxanthoma Elasticum

Defective type III collagen synthesis without elastic fiber calcification

Calcification and fragmentation of elastic fibers in skin, eyes, and arteries

Thin, translucent skin with visible veins

Yellowish papules and plaques with peau d’orange appearance

No characteristic retinal findings

Angioid streaks in the retina

Ehlers-Danlos Syndrome (Vascular Type) versus Cutis Laxa

Ehlers-Danlos Syndrome (Vascular Type)

Cutis Laxa

Thin, translucent skin with visible veins

Loose, sagging, inelastic skin without translucency

Autosomal dominant mutation in COL3A1 gene

Can be autosomal dominant, recessive, or acquired

Frequent arterial and organ rupture

Rare vascular rupture

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.